Results 71 to 80 of about 82,604 (202)

Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross‐sectional and longitudinal analysis using two large national registries

Cancer Medicine, 2021
Background Cardiovascular adverse events (CVAEs) associated with BRAF inhibitors alone versus combination BRAF/MEK inhibitors are not fully understood. Methods This study included all adult patients who received BRAF inhibitors (vemurafenib, dabrafenib ...
Avirup Guha, Prantesh Jain, Michael G. Fradley, Daniel Lenihan, Jahir M. Gutierrez, Chhavi Jain, Marcos deLima, Jill S. Barnholtz‐Sloan, Guilherme H. Oliveira, Afshin Dowlati, Sadeer Al‐Kindi   +10 more
doaj   +1 more source

FOXD3 Regulates VISTA Expression in Melanoma. [PDF]

, 2020
Immune checkpoint inhibitors have improved patient survival in melanoma, but the innate resistance of many patients necessitates the investigation of alternative immune targets.
Aplin, Andrew E., Berger, Adam C., Chervoneva,, Davies, Michael A., Erkes, Dan A., Fisher, David E., Gershenwald, Jeffrey E., Knecht, Meghan, Lo, Jennifer A., McCue, Peter A., Mollaee, Mehri, Purwin, Timothy J., Rosenbaum, Sheera R., Zhong, Zhijiu   +13 more
core   +1 more source

Recent advances in managing differentiated thyroid cancer [PDF]

, 2018
The main clinical challenge in the management of thyroid cancer is to avoid over-treatment and over-diagnosis in patients with lower-risk disease while promptly identifying those patients with more advanced or high-risk disease requiring aggressive ...
Durante, Cosimo, Filetti, Sebastiano, Grani, Giorgio, Lamartina, Livia   +3 more
core   +2 more sources

Resistant mechanisms to BRAF inhibitors in melanoma [PDF]

Annals of Translational Medicine, 2016
Patients with advanced melanoma have traditionally had very poor prognosis. However, since 2011 better understanding of the biology and epidemiology of this disease has revolutionized its treatment, with newer therapies becoming available. These newer therapies can be classified into immunotherapy and targeted therapy.
Manzano, José Luis, Layos, Laura, Bugés, Cristina, Llanos Gil, María de los, Vila, Laia, Martínez Balibrea, Eva, Martínez Cardús, Anna   +6 more
openaire   +3 more sources

The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma. [PDF]

, 2018
Despite major advances in targeted melanoma therapies, drug resistance limits their efficacy. Long noncoding RNAs (lncRNAs) are transcriptome elements that do not encode proteins but are important regulatory molecules.
Burlingame, Alma, Daud, Adil, Dimon, Michelle, Esteve-Puig, Rosaura, Gajjala, Abhinay, Gho, Deborah, Ho, Wilson, Johnston, Katia, Lai, Kevin, Lin, Kevin, Moy, Adrian, Ortiz-Urda, Susana, Oses Prieto, Juan, Posch, Christian, Rappersberger, Klemens, Sanlorenzo, Martina, Vujic, Igor, Vujic, Marin, Zekhtser, Mitchell   +18 more
core   +1 more source

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors

Acta Dermato-Venereologica
The prognostic value of BRAF V600 mutation level on clinical outcomes in patients with BRAF V600-mutated metastatic melanoma treated with BRAF and MEK inhibitors remains uncertain.
Ariane Fizazi, Chris Serrand, Alexandre Evrard, Blanche Bergeret, Pierre-Emmanuel Stoebner, Myriam Marque   +5 more
doaj   +1 more source

The paradox of cancer genes in non-malignant conditions: implications for precision medicine. [PDF]

, 2020
Next-generation sequencing has enabled patient selection for targeted drugs, some of which have shown remarkable efficacy in cancers that have the cognate molecular signatures.
Adashek, Jacob J, Kato, Shumei, Kurzrock, Razelle, Lippman, Scott M   +3 more
core  

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. [PDF]

, 2019
BackgroundThis pooled analysis investigated the prognostic value of depth of response in two cohorts of patients with BRAFV600-mutated metastatic melanoma treated with vemurafenib or cobimetinib plus vemurafenib.MethodsThe data were pooled from BRIM-2 ...
Ascierto, Paolo A, Dréno, Brigitte, Flaherty, Keith T, Hauschild, Axel, Larkin, James, Lewis, Karl D, McArthur, Grant A, McKenna, Edward, Mun, Yong, Ribas, Antoni, Wongchenko, Matthew, Yan, Yibing, Zhu, Qian   +12 more
core   +2 more sources

Frontiers in Pigment Cell and Melanoma Research

, 2018
We identify emerging frontiers in clinical and basic research of melanocyte biology and its associated biomedical disciplines. We describe challenges and opportunities in clinical and basic research of normal and diseased melanocytes that impact current ...
Birlea, Stanca, Bosenberg, Marcus W., Box, Neil F., Brash, Douglas, Cassidy, Pamela B., Chen, Suzie, D'Orazio, John August, Filipp, Fabian V., Fujita, Mayumi, Goh, Boon-Kee, Herlyn, Meenhard, Indra, Arup K., Larue, Lionel, Leachman, Sancy A., Liu-Smith, Feng, Manga, Prashiela, Montoliu, Lluis, Norris, David A., Poole, Caroline Le, Shellman, Yiqun, Smalley, Keiran S. M., Spritz, Richard A., Sturm, Richard A., Swetter, Susan M., Terzian, Tamara, Wakamatsu, Kazumasa, Weber, Jeffrey S.   +26 more
core   +1 more source

Disrupting ATF4 Expression Mechanisms Provides an Effective Strategy for BRAF-Targeted Melanoma Therapy

iScience, 2020
Summary: BRAF V600 mutation influences cellular signaling pathways for melanoma development. However, the role of oncogenic BRAF in adaptive stress response pathways is not fully understood.
Ikuko Nagasawa, Masaru Koido, Yuri Tani, Satomi Tsukahara, Kazuhiro Kunimasa, Akihiro Tomida   +5 more
doaj   +1 more source